Decreased bone density and stature can occur in pediatric patients with inflammatory bowel disease (IBD). Little is known about how IBD broadly impacts the skeleton. To evaluate the influence of an acute episode of IBD on growing bone, 4 week-old mice were administered 5% dextran sodium sulfate (DSS) for 5 days to induce colitis and their recovery monitored. During active disease and early recovery, trabecular bone mineral density, bone volume and thickness were decreased. Cortical bone thickness, outer perimeter and density were also decreased while inner perimeter and marrow area were increased. These changes appear to maintain bone strength since measures of moments of inertia were similar between DSS-treated and control mice. Histological (static and dynamic), serum and RNA analyses indicate that a decrease in osteoblast maturation and function account for changes in bone density. Unlike some conditions of bone loss, marrow adiposity did not increase. Similar to reports in humans, bone length decreased and correlated with decreases in growth plate thickness and chondrocyte marker expression. During disease recovery, mice experienced a growth spurt that lead to their achieving final body weights and bone length, density, and gene expression similar to healthy controls. Increased TNF and decreased IGF-1 serum levels were observed with active disease and returned to normal with recovery. Changes in serum TNF (increased) and IGF-1 (decreased) paralleled changes in bone parameters and returned to normal values with recovery, suggesting a potential role in the skeletal response.